Array BioPharma, Inc.
3200 Walnut Street
Boulder
Colorado
80301
United States
Tel: 303-381-6600
Fax: 303-381-6697
Website: http://www.arraybiopharma.com/
Email: bd@arraybiopharma.com
467 articles about Array BioPharma, Inc.
-
Array BioPharma to Present Updated Phase III BEACON CRC Safety Lead-In Results of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the 2018 Gastrointestinal Cancers Symposium
1/17/2018
These data will be presented at the 2018 ASCO GI in San Francisco, California.
-
ASLAN Pharmaceuticals Pays $129M to Acquire Full Global Commercial Rights for Varlitinib From Arr...
1/3/2018
The new licensing agreement replaces the prior licensing agreement signed in 2011 to develop and sublicense varlitinib, which did not grant commercial rights to ASLAN. -
ASLAN Pharma Acquires Full Global Commercial Rights for Varlitinib From Array BioPharma
1/3/2018
The new licensing agreement replaces the prior licensing agreement signed in 2011 to develop and sublicense varlitinib, which did not grant commercial rights to ASLAN.
-
It appears that what Array is trying to do is focus on oncology while the new subsidiary focuses on rare diseases.
-
Array BioPharma announced today that it has entered into a clinical trial collaboration agreement with Pfizer to investigate the safety and efficacy of several novel anti-cancer combinations.
-
Array BioPharma Announces Redemption of All Remaining 3.00% Convertible Senior Notes Due 2020
12/5/2017
The redemption will be made in accordance with the terms of the indenture governing the 2020 Notes and the terms of the redemption notice.
-
Array BioPharma Announces Private Exchange of $107M of its 3.00% Convertible Senior Notes Due 2020 for its 2.625% Convertible Senior Notes Due 2024 and Shares of its Common Stock
11/17/2017
The Company anticipates that the settlement of the transactions under the exchange agreements will occur on or about December 1, 2017, subject to satisfaction of customary closing conditions.
-
Array BioPharma Reports Initial Results From Novel Immunotherapy Combination at the SITC 32nd Annual Meeting
11/13/2017
Array BioPharma today announced data from the Phase Ib clinical trial evaluating the immunotherapy combination of ARRY-382, with Merck's KEYTRUDA at the SITC 32nd Annual Meeting, being held Nov. 8-12, 2017 in National Harbor, Maryland.
-
Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2018
10/31/2017
Array BioPharma today reported results for its first quarter of fiscal 2018 and provided an update on the progress of its key clinical development programs.
-
Array Biopharma to Report Financial Results for the First Quarter of Fiscal 2018 On October 31, 2017
10/25/2017
Array BioPharma will report financial results for the first quarter of fiscal 2018 and hold a conference call to discuss those results on Tuesday, October 31, 2017.
-
Array BioPharma Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares
9/19/2017
-
Array BioPharma Announces Pricing Of Public Offering Of Common Stock
9/15/2017
-
Array BioPharma Announces Proposed Public Offering Of Common Stock
9/14/2017
-
Array BioPharma Announces FDA Acceptance For Review Of Binimetinib And Encorafenib New Drug Applications For Patients With Advanced BRAF-mutant Melanoma
9/12/2017
-
Array BioPharma Release: Phase III COLUMBUS Part 2 Results In BRAF-Mutant Melanoma Presented At European Society For Medical Oncology Congress
9/11/2017
-
Array BioPharma Release: Phase III BEACON CRC Safety Lead-In Results In BRAF-Mutant Colorectal Cancer Presented At European Society For Medical Oncology Congress
9/11/2017
-
Array BioPharma To Present BEACON CRC Safety Lead-In And COLUMBUS Part 2 Results At European Society For Medical Oncology Congress (ESMO)
8/30/2017
-
Array BioPharma Appoints Curtis Oltmans As General Counsel
8/15/2017
-
Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017
8/9/2017
-
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 On August 9, 2017
8/3/2017